FILTER

FILTERED INTERVIEW RESULTS

Mining
Peru

Víctor Gobitz

PRESIDENT, PERUVIAN INSTITUTE OF MINING ENGINEERS (IIMP)
IIMP’s President discusses the impact of COVID-19 on Peru’s mining industry.
Mining
Peru

John Black

CEO AND DIRECTOR, REGULUS RESOURCES
Regulus Resources updates GBR on its developments at the AntaKori copper-gold project in Peru, where it has already demonstrated a sizeable resource with great opportunity for expansion.
Mining
Peru

Augusto F. Cauti

VICE MINISTER OF MINES, MINISTRY OF ENERGY AND MINES (MINEM) – GOVERNMENT OF PERU
The Ministry of Energy and Mines of Peru (MINEM) outlines its plans to maintain the growth of the county’s vital mining industry.
Mining
Peru

David Stein

PRESIDENT, KUYA SILVER
Kuya Silver outlines its plans for the Bethania silver mine that it is developing in Peru.
Peru
Pharma & Life Sciences

Ángela Flores

EXECUTIVE DIRECTOR, ALAFARPE
An overview of Peru’s pharmaceutical market.
Mining
Peru

Paul Murphy

MANAGER – SOUTH AMERICA, MINING PLUS
Mining Plus explains the trends that are effecting its business in Peru and South America more generally.
Mining
Peru

Edgardo Orderique

GENERAL MANAGER – OPERATIONS, MMG-LAS BAMBAS
MMG-Las Bambas discusses operational improvements, tailings management, and plans for the future.
Mining
Peru

Carla Martínez

GENERAL MANAGER, CANADA PERU CHAMBER OF COMMERCE (CCCP)
A discussion about the challenges and opportunities for Canadian investors in Peru’s mining industry.
Mining
Peru

Víctor Gobitz

CEO, BUENAVENTURA
Buenaventura outlines progress at its diverse portfolio of Peruvian assets.
Mining
Peru

César Inostroza

SENIOR VICE-PRESIDENT, MINING & METALLURGY, SNC-LAVALIN
Peru Mining 2019 Pre-Release Edition 2
SNC-Lavalin is benefitting from a resurgence in the mining industry and is upgrading capabilities across its business groups.

MACIG

SPANISH

SUBSCRIBE TO OUR NEWSLETTER

RECENT PUBLICATIONS

United States Life Sciences 2025 - Digital Interactive

Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
MORE PREVIOUSLY PUBLISHED

PARTNER EVENTS

SEE ALL